Johnson T M, El-Defrawy S, Hodge W G, Leonard B C, Kertes P J, Lillicrap D P
University of Ottawa Eye Institute, Ontario, Canada.
Retina. 2001;21(2):161-6. doi: 10.1097/00006982-200104000-00010.
Factor V Leiden is a common inherited mutation that is a significant risk factor for deep vein thrombosis. It results in resistance to activated protein C (APC). The association between factor V Leiden and central retinal vein occlusion (CRVO) remains controversial. This study was designed to determine the prevalence of APC resistance and the factor V Leiden mutation in patients with CRVO in a controlled study.
The study was designed as a case control study conducted in a tertiary care retina practice. The prevalence of APC resistance and factor V Leiden was determined by genetic testing of blood samples obtained from patients with CRVO and clinic control patients.
Factor V Leiden was identified in 2.3% of patients with CRVO and 3.5% of clinic control patients. There was no significant association between the presence of factor V Leiden and CRVO (odds ratio, 1.13; 95% confidence interval, 0.65-1.98; P = 0.66).
Factor V Leiden does not appear to be associated with CRVO. Routine screening of patients with CRVO does not appear to be warranted.
凝血因子V莱顿突变是一种常见的遗传性突变，是深静脉血栓形成的重要危险因素。它会导致对活化蛋白C（APC）产生抵抗。凝血因子V莱顿突变与视网膜中央静脉阻塞（CRVO）之间的关联仍存在争议。本研究旨在通过一项对照研究确定CRVO患者中APC抵抗和凝血因子V莱顿突变的患病率。
本研究设计为在三级医疗视网膜诊所进行的病例对照研究。通过对CRVO患者和临床对照患者采集的血样进行基因检测，确定APC抵抗和凝血因子V莱顿突变的患病率。
在2.3%的CRVO患者和3.5%的临床对照患者中检测到凝血因子V莱顿突变。凝血因子V莱顿突变的存在与CRVO之间无显著关联（比值比，1.13；95%置信区间，0.65 - 1.98；P = 0.66）。
凝血因子V莱顿突变似乎与CRVO无关。对CRVO患者进行常规筛查似乎没有必要。
Zotero 插件